Phase 1/2a study of Lu-177-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA2202D35" target="_blank" >RIV/61988987:17110/20:A2202D35 - isvavai.cz</a>
Result on the web
<a href="https://ashpublications.org/bloodadvances/article/4/17/4091/463597/Phase-1-2a-study-of-177Lu-lilotomab-" target="_blank" >https://ashpublications.org/bloodadvances/article/4/17/4091/463597/Phase-1-2a-study-of-177Lu-lilotomab-</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/bloodadvances.2020002583" target="_blank" >10.1182/bloodadvances.2020002583</a>
Alternative languages
Result language
angličtina
Original language name
Phase 1/2a study of Lu-177-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
Original language description
For patients with indolent non-Hodgkin lymphoma who fail initial anti-CD20-based immunochemotherapy or develop relapsed or refractory disease, there remains a significant unmet clinical need for new therapeutic approaches to improve outcomes and quality of life. Lu-177-lilotomab satetraxetan is a next-generation single-dose CD37-directed radioimmunotherapy (RIT) which was investigated in a phase 1/2a study in 74 patients with relapsed/refractory indolent non-Hodgkin B-cell lymphoma, including 57 patients with follicular lymphoma (FL). To improve targeting of Lu-177-lilotomab satetraxetan to tumor tissue and decrease hematologic toxicity, its administration was preceded by the anti-CD20 monoclonal antibody rituximab and the 'cold' anti-CD37 antibody lilotomab. The most common adverse events (AEs) were reversible grade 3/4 neutropenia (31.6%) and thrombocytopenia (26.3%) with neutrophil and platelet count nadirs 5 to 7 weeks after RIT. The most frequent nonhematologic AE was grade 1/2 nausea (15.8%). With a single administration, the overall response rate was 61% (65% in patients with FL), including 30% complete responses. For FL with >= 2 prior therapies (n = 37), the overall response rate was 70%, including 32% complete responses. For patients with rituximab-refractory FL >= 2 prior therapies (n = 21), the overall response rate was 67%, and the complete response rate was 24%. The overall median duration of response was 13.6 months (32.0 months for patients with a complete response). Lu-177-lilotomab satetraxetan may provide a valuable alternative treatment approach in relapsed/refractory non-Hodgkin lymphoma, particularly in patients with comorbidities unsuitable for more intensive approaches.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
BLOOD ADVANCES
ISSN
2473-9529
e-ISSN
—
Volume of the periodical
4
Issue of the periodical within the volume
17
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
4091-4101
UT code for WoS article
000567426100007
EID of the result in the Scopus database
2-s2.0-85096054131